Brazilian health regulator Anvisa said testing of Russia's Sputnik-V COVID-19 vaccine has not begun in Brazil, as reported in the Financial Post.
A spokeswoman for the agency said Brazil's Paraná and Bahia states, which have testing and production or distribution agreements for Sputnik-V, have not yet filed requests for clinical trials in the country.
"There have been numerous meetings, physical and online, with no documents on the Russian vaccine materializing yet," she remarked.
The Russian Direct Investment Fund (RDIF), which is marketing Sputnik-V, did not immediately reply to a request for comment.
Meanwhile, trials for the vaccine developed by AstraZeneca and Oxford University, and another potential vaccine by China's Sinovac Biotech are being conducted at a dozen sites and initial data sent in to Anvisa.
"This is still not a formal request for registration of these vaccines. We will only consider that when all the documents have been filed," the spokeswoman noted.
To read more NewsPoints articles, click here.